L-.beta.-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US5792773A · kind A · utility
17Cited by
7References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 15, 1996 |
| Grant date | Aug 11, 1998 |
| Priority date | — |
| Expiry date | Nov 15, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to the discovery that certain .beta.-L-dioxolane nucleoside analogs which contain a uracil base, and preferably, a 5-halosubstituted uracil base, exhibit unexpectedly high activity against Epstein-Barr virus (EBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds are useful for treating EBV infections in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.